Obagi Medical announced the launch of the Aesthetic Leadership with Obagi Hyaluronic Acid Program. This structured clinical collaboration initiative accelerates aesthetic innovation through practice-led insights and will support the introduction of Obagi saypha MagIQ- the company’s first FDA-approved injectable hyaluronic acid filler. The ALOHA program creates a platform for practices to integrate real-world clinical experience into the product lifecycle. Participants will incorporate Obagi saypha MagIQ into routine treatments and provide structured feedback via standardized surveys from injectors and practice owners. This authentic, practice-driven approach captures insights beyond pivotal trials, informing post-launch education, scientific content, and wider adoption.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast Shareholders Back Board Slate and Auditor at January 2026 AGM
- Waldencast assumed with a Buy at Jefferies
- Waldencast Sets January 2026 AGM and Reshapes Board Following Director Resignations
- Waldencast files to sell 9.82M Class A ordinary shares for holders
- Waldencast downgraded at Telsey Advisory after ‘disappointing’ Q2 results